-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China shows that Novartis's classic dual-target combination therapy-dabrafenib/trametinib is planned to be included in the priority review and is suitable for the treatment of BRAF V600 mutation-positive patients.
It is suitable for the treatment of patients with advanced non-small cell lung cancer with BRAF V600 mutation positive
Screenshot source: CDE official website
Dabrafenib and trametinib target different kinases in the serine/threonine kinase family in the RAS/RAF/MEK/ERK pathway, BRAF and MEK1/2 , respectively.
Respectively target different kinases in the serine/threonine kinase family in the RAS/RAF/MEK/ERK pathway-BRAF and MEK1/2
It is worth mentioning that tadalafil Nepal and the United States original song by GlaxoSmithKline (GSK) has imatinib, codenamed respectively GSK2118436 and GSK1120212.
Novartis acquired the latter's oncology business for a total of $16 billion in cash consideration
In China, the dabrafenib/trametinib combination therapy was first approved for marketing in China in December 2019 to treat BRAF V600 mutation-positive unresectable or metastatic melanoma
The dabrafenib/trametinib combination therapy was first approved for marketing in China in December 2019.
Because these mutant tumors are more malignant and respond poorly to standard chemotherapy, they are more likely to lead to poor prognosis
Screenshot source: CDE official website
As early as June 2017, dabrafenib/trametinib combination therapy has been approved by the U.
For the treatment of non-small cell lung cancer patients whose tumors carry BRAF V600E mutations, the overall response rate (ORR) reached 61%, and the ORR reached 63%
According to a press release issued by Novartis earlier, this is an important milestone in the field of lung cancer
This is an important milestone in the field of lung cancer
Reference materials:
Reference materials:[1] Center for Drug Evaluation (CDE) of China National Medical Products Administration.
[2] Tefila (dalafenib) and Meginine (trametinib) were approved to be listed in China.
[3] Dual-target therapy for double happiness—Tefir® and Maijining® were approved for adjuvant therapy indications.
[4] Novartis AG (NVS) Combination Targeted Therapy Tafinlar + Mekinist Receives FDA Approval For BRAF V600E Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC).
Retrieved Jun 22.
2017.
from https:// -releases/novartis-combination-targeted-therapy-tafinlar-mekinist-receives-fda-approval-braf-v600e-mutant-metastatic-non-small-cell-lung-cancer-nsclc#:~:text=Basel%2C% 20June%2022%2C%202017%20-%20Novartis%20today%20announced,%28NSCLC%29%20whose%20tumors%20express%20the%20BRAF%20V600E%20mutation.